Related posts
Markets stabilizeThis summary was created by AI, based on 10 opinions in the last 12 months.
Experts have mixed opinions on Vertex Pharmaceuticals Inc. Some are disappointed with the news on their wonder drug and do not see upside for the company. Others are optimistic about the potential FDA approvals for their non-addictive painkillers. The company's anti-pain drug has received positive feedback, but concerns remain about negative free cash flow. Overall, Vertex Pharmaceuticals Inc. is seen as a company with potential, but also facing challenges.
He likes it for developing non-addictive painkillers with potential FDA approvals ahead. They reported a great quarter a day before the election, but has since pulled back hard that baffles him. Looks like profit-taking in a stock that's jumped 113% since end-2021.
Their anti-pain drug is not addictive and it works. He's a believer.
Negative free cash flow to enter 2024, but it's turning positive. Shares are up 21% this year.
Even at this all time high don't sell. They're working on non-addictive painkillers
It's doing well, hitting new highs today. It's further along in its life cycle. Has a fine cystic fibrosis franchise. Shares are strong momentum, so he's staying in.
This drugmaker has a lock on MS and have new shots on pain management and other maladies. Lots going on. Up sharply this month.
Likes it, but she trimmed it because a lot of the good news from its pain medicine is now in the stock.
PPH, an ETF for pharma producers, is breaking out and near a record. VTX and Eli Lilly are leaders in this space and Vertex has a great product for Cystic Fibrosis therapeutics. It is growing well and not too expensive.
They're in the MS business, so will they expand beyond MS? HE's confident they will and have some hit drugs.
A high-quality biopharma with a strong cystic fibrosis drug. Are trying to get into other franchises like diabetes treatments. Will do well long-run. Trades at 23x with 11% earnings growth, so you can take some profits now. Had a good run, so take some money off the table.
Vertex Pharmaceuticals Inc. is a American stock, trading under the symbol VRTX-Q on the NASDAQ (VRTX). It is usually referred to as NASDAQ:VRTX or VRTX-Q
In the last year, 10 stock analysts published opinions about VRTX-Q. 6 analysts recommended to BUY the stock. 2 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Vertex Pharmaceuticals Inc..
Vertex Pharmaceuticals Inc. was recommended as a Top Pick by on . Read the latest stock experts ratings for Vertex Pharmaceuticals Inc..
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
10 stock analysts on Stockchase covered Vertex Pharmaceuticals Inc. In the last year. It is a trending stock that is worth watching.
On 2025-01-14, Vertex Pharmaceuticals Inc. (VRTX-Q) stock closed at a price of $411.66.
They got disappointing news on their wonder drug. Disappointing. Doesn't see upside for the company.